EGFR and cancer: Van Den Bent et al. (NCT02343406) conducted the INTELLANCE 2/European Organization for Research and Treatment of Cancer (EORTC) 1410 phase II study, a multicenter three-arm comparative, randomized trial with 260 patients with EGFR-amplified rGBM, utilizing Depatux-M with or without TMZ [117].